Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and will present two preclinical posters at the AACR Annual Meeting in April 2026 [1][2] Group 1: Poster Presentation Details - The first poster titled "Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha" will be presented on April 20, 2026, from 2:00-5:00pm PT [2] - The second poster titled "Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures" will also be presented on April 20, 2026, from 2:00-5:00pm PT [2] Group 2: Company Overview - Olema Oncology is committed to transforming the standard of care for patients with breast cancer, advancing a pipeline of novel therapies based on a deep understanding of endocrine-driven cancers [3] - The lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials and is a proprietary, orally available complete estrogen receptor antagonist and selective estrogen receptor degrader [3][4] - OP-3136, another candidate, is a potent KAT6 inhibitor currently in a Phase 1 clinical study, having shown significant anti-proliferative activity in ER+ breast cancer models [5]

Core Viewpoint - Olema Pharmaceuticals Inc. is focused on developing targeted therapies for women's cancers, particularly breast cancer, with its leading project being Palazestrant, a new class of treatments [1][4] Company Overview - Olema Pharmaceuticals Inc. is a biopharmaceutical company dedicated to women's cancer therapies, with strategic collaborations with pharmaceutical giants like Pfizer Inc. and Novartis AG [1][4] - The company's leading project, Palazestrant, is a complete estrogen receptor antagonist and selective estrogen receptor degrader [1] Stock Performance - On March 9, 2026, H.C. Wainwright set a price target of $38 for Olema, indicating a potential upside of approximately 69% from a trading price of $16.45 [2] - The stock has recently declined to $16.30, marking a decrease of 24.36% from its previous price, attributed to disappointing results from Roche Holdings AG's phase 3 study [2] - Olema's stock has shown significant volatility, with a trading range over the past year between $2.86 and $36.26, and a market capitalization of approximately $1.28 billion [3][4]

Core Viewpoint - Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is experiencing a decline due to disappointing results from Roche Holdings AG's phase 3 persevERA Breast Cancer study involving giredestrant combined with palbociclib, which did not meet its primary objective of improving progression-free survival significantly [1][2] Company Performance - Olema's lead product candidate, Palazestrant, is a novel orally available complete estrogen receptor antagonist (CERAN) and SERD [3] - The stock is currently trading 26.2% below its 20-day simple moving average (SMA) and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term [4] - Over the past 12 months, shares have increased by 294.05%, but they are closer to their 52-week lows than highs [4] Technical Indicators - The Relative Strength Index (RSI) is at 34.36, indicating neutral territory, while the MACD shows a value of -0.6379, below its signal line at -0.5304, suggesting bearish pressure on the stock [5] - The combination of neutral RSI and bearish MACD reflects uncertainty in the stock's near-term outlook [5] Analyst Consensus - The stock carries a Buy Rating with an average price target of $37.33 [6] - Recent analyst actions include: - HC Wainwright & Co. maintained a Buy rating with a target raised to $38 on March 9 [6] - Stifel initiated coverage with a Buy rating and a target of $48 on February 11 [6] - UBS initiated coverage with a Buy rating and a target of $45 on January 7 [6] - Piper Sandler initiated with Overweight on January 7 [6] - At the time of publication, Olema Pharmaceuticals shares were down 20.46% at $17.14 [6]

Core Viewpoint - Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is identified as a promising small-cap stock with significant growth potential, particularly due to its drug Palazestrant, which targets ER+/HER2- breast cancer [1][2]. Group 1: Analyst Ratings and Price Targets - Sam Slutsky from LifeSci Capital has reiterated a Buy rating on Olema Pharmaceuticals and raised the price target from $39 to $45 [1]. - Kelsey Goodwin from Piper Sandler also maintained a Buy rating with a price target of $40 [1]. Group 2: Drug Development and Market Potential - The bullish rating from Piper Sandler is primarily based on the capabilities of Palazestrant, which is expected to be a best-in-class treatment for ER+/HER2- breast cancer due to its complete ER antagonism and degradation ability [2]. - Olema Pharmaceuticals is planning multiple phase 3 trials for Palazestrant in 2026, which could further enhance the stock's value [3]. - The company anticipates launching Palazestrant by next year, indicating a strong focus on developing treatments for breast cancer and other serious diseases [3].

Company Overview - Olema aims to improve treatments for patients with ER-positive HER2-negative breast cancer, addressing significant unmet needs in this common cancer indication [1] Clinical Programs - Olema has two programs in the clinic: one in Phase III trials and one in Phase I/Phase Ib [2] - The lead asset, palazestrant, is a complete estrogen receptor antagonist, which is believed to be the best endocrine therapy for ER-positive HER2-negative breast cancer [2] Treatment Approach - Endocrine therapy is the backbone of treatment for ER-positive HER2-negative breast cancer, as the estrogen receptor is a primary driver of tumor growth and proliferation [3] - Palazestrant is currently in a first-line trial in combination with ribociclib, marking it as the only first-line trial of a CERAN/SERD in the endocrine-sensitive wild-type ESR1 setting [3] - Additionally, palazestrant is involved in a second third-line trial, OPERA-01, as a monotherapy [3]

Palazestrant (OP-1250) Development - Olema aims to establish Palazestrant as a best-in-class backbone therapy for ER+/HER2- breast cancer, both as a monotherapy and in combination with other anti-tumor agents[8] - The pivotal Phase 3 OPERA-01 clinical trial of Palazestrant as a monotherapy is ongoing, with top-line results expected in 2026[16, 37] - A pivotal Phase 3 OPERA-02 clinical trial of Palazestrant in combination with ribociclib is planned for initiation in 2025[3, 14, 16, 37, 88] - Palazestrant monotherapy Phase 2 data showed a median PFS of 73 months in 2/3L ±CT ESR1-mutant patients and 55 months in 2/3L ±CT ESR1-wild-type patients[45, 46, 47] - Palazestrant, at 120mg in combination with ribociclib, showed a 6-month PFS rate of 74% in all patients and 68% in patients with prior CDK4/6i[75, 80] OP-3136 (KAT6 Inhibitor) Development - Olema is advancing the clinical development of OP-3136, a potential best-in-class KAT6 inhibitor, in breast and other solid tumor cancers[10] - The FDA has cleared the Investigational New Drug (IND) application for OP-3136, and a Phase 1 clinical trial has been initiated[16, 100] - Preclinical data demonstrates that OP-3136 shows synergistic activity in combination with palazestrant[112] Market and Financial Position - The estimated global market for ER+/HER2- metastatic breast cancer is greater than $20 billion[35] - The U S market potential for Palazestrant in the 2/3L setting is estimated at $3-5 billion[63] - Olema has a strong capital position with $3927 million[13]